ID: ALA99365

Max Phase: Preclinical

Molecular Formula: C27H30N2O6S

Molecular Weight: 510.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(COc2ccc(S(=O)(=O)CC(CC3CCC(=O)CC3)N(O)C=O)cc2)c2ccccc2n1

Standard InChI:  InChI=1S/C27H30N2O6S/c1-19-14-21(26-4-2-3-5-27(26)28-19)16-35-24-10-12-25(13-11-24)36(33,34)17-22(29(32)18-30)15-20-6-8-23(31)9-7-20/h2-5,10-14,18,20,22,32H,6-9,15-17H2,1H3

Standard InChI Key:  YFYQFPIGOKJLFD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 510.61

Molecular Weight (Monoisotopic): 510.1825

AlogP: 4.26

#Rotatable Bonds: 10

Polar Surface Area: 113.87

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.22

CX Basic pKa: 5.02

CX LogP: 3.15

CX LogD: 3.09

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.25

Np Likeness Score: -0.69

References

1. Kamei N, Tanaka T, Kawai K, Miyawaki K, Okuyama A, Murakami Y, Arakawa Y, Haino M, Harada T, Shimano M..  (2004)  Reverse hydroxamate-based selective TACE inhibitors.,  14  (11): [PMID:15125955] [10.1016/j.bmcl.2004.03.048]

Source

Source(1):

• Scientific Literature